SCYNEXIS to Participate in the H.C. Wainwright 27th Annual Global Conference September 8

Core Insights - SCYNEXIS, Inc. is a biotechnology company focused on developing innovative medicines to combat difficult-to-treat and drug-resistant infections [2] Group 1: Company Overview - SCYNEXIS is pioneering a proprietary antifungal platform known as "fungerps" [2] - Ibrexafungerp, the first drug from this novel class, has been licensed to GSK and received FDA approval for vulvovaginal candidiasis (VVC) in June 2021, with a second indication approved in November 2022 for reducing recurrent VVC [2] - The company is conducting late-stage clinical investigations of ibrexafungerp for life-threatening invasive fungal infections in hospitalized patients [2] - Additional antifungal compounds from the "fungerps" class, including SCY-247, are in various stages of clinical and pre-clinical development [2] Group 2: Upcoming Events - The senior leadership team of SCYNEXIS will participate in the H.C. Wainwright 27th Annual Global Conference on September 10, 2025 [1] - The presentation will take place from 10:30 a.m. to 11:00 a.m. ET in New York, NY, and will include in-person presentations and one-on-one meetings [1]